Moderna Therapeutics

Alexion, Moderna end partnership

Tuesday, August 1, 2017

Moderna Therapeutics, a clinical stage biotechnology company that is pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, provided an update on its rare disease Research & Development (R&D) strategy, issuing the following statement related to Alexion Pharmaceuticals R&D realignment announcement.

[Read More]

PureTech, Siddhartha Mukherjee launch Vor BioPharma

Wednesday, May 11, 2016

PureTech Health has launched Vor BioPharma, an immuno-oncology company dedicated to developing a new class of targeted cell therapies. The company, which is advancing a novel approach to chimeric antigen receptor (CAR) T-cell therapy, has licensed its core technology from the lab of Vor scientific co-founder, Siddhartha Mukherjee, M.D., Ph.D., assistant professor of Medicine at Columbia University and Pulitzer Prize-winning author of The Emperor of All Maladies: A Biography of Cancer.

[Read More]

Moderna, Merck to develop messenger RNA-based antiviral vaccines

Wednesday, January 14, 2015

Moderna Therapeutics has announced a license and collaboration agreement with Merck, through a subsidiary, for the discovery and development of vaccines and passive immunity treatments against viral diseases using modified messenger RNA (mRNA). Moderna’s work in the collaboration will be led by Valera, its venture focused on the development of mRNA vaccines and therapeutics to fight infectious disease. Moderna is privately held, Cambridge, Mass.-based company founded by Flagship VentureLabs.

[Read More]

Moderna, Karolinska Institute to collaborate on messenger RNA therapeutics

Thursday, October 16, 2014

Moderna Therapeutics, a Cambridge, Mass.-based pharma, has formed a strategic, long-term collaboration with Karolinska Institute (KI) and Karolinska University Hospital (KUH), both in Sweden, for the discovery and development of innovative drugs using Moderna’s messenger RNA (mRNA) Therapeutics technology. mRNA Therapeutics enable the in vivo production of both intracellular proteins and secreted proteins.

[Read More]